Breaking news on Blood and Haematology News
Supporting Minority Medical Students To Increase Diversity In Hematology published
Fri, 09 May 2008 05:00:00 PDT
The American Society of Hematology (ASH) is proud to announce the selection of 15 participants for its 2008 Minority Medical Student Award Program (MMSAP), which encourages minority medical students to purse an interest in hematology research. Under the program, each award recipient will receive the support of a research mentor and a career development mentor, travel stipends to attend medical meetings, and a subscription to the scientific journal Blood, the official journal of ASH.
New Study Shows How Genes Control Blood Proteins Important To Health published
Fri, 09 May 2008 03:00:00 PDT
A new study shows how genes control levels of many blood proteins implicated in disease. The findings are the result of an international collaboration between scientists at the University of Exeter, the National Institute on Aging, and the Tuscany and Florence Health Agencies. Details, published May 9th in the open-access journal
Lev Pharmaceuticals Announces Cinryze(TM) Complete Response Submission Accepted For Review By FDA published
Thu, 08 May 2008 02:00:00 PDT
Lev Pharmaceuticals, Inc. (OTCBB: LEVP.OB) announced that the U.S. Food and Drug Administration (FDA) has accepted for review Lev's complete response submission for Cinryze™ (C1 inhibitor), the Company's lead product candidate. Lev is seeking marketing approval for Cinryze™ for both the acute and prophylactic treatment of hereditary angioedema (HAE), also known as C1 inhibitor deficiency.
Heart Attack Injury Lessened And Function Restored By Naturally-Occuring Protein published
Wed, 07 May 2008 03:00:00 PDT
Medical College of Wisconsin researchers in Milwaukee have shown for the first time that thrombopoietin (TPO), a naturally occurring protein being developed as a pharmaceutical to increase platelet count in cancer patients during chemotherapy, can also protect the heart against injury during a heart attack.The study, led by John E.
ParagonDx Receives FDA 510(k) Marketing Clearance For Warfarin Sensitivity Genotyping Kit published
Wed, 07 May 2008 02:00:00 PDT
ParagonDx, a leader in genetic testing diagnostics, has received 510(k) marketing clearance from the US Food and Drug Administration (FDA) for its in vitro diagnostic test. The Rapid Genotyping Assay is to be used to detect the presence of variations in the genes CYP2C9 and VKORC1. Information about the CYP2C9 and VKORC1 genotypes may be used as an aid in the identification of patients at greater risk for warfarin sensitivity.
New Formulation Of Medication For Rare Disease Patients published
Wed, 07 May 2008 01:00:00 PDT
A new treatment option - Ferriprox Oral Solution - is now available to patients suffering from thalassaemia major, a rare genetic disease with only 50 percent of the patients surviving the age of 35 years1. Thalassaemia patients require blood transfusions to survive, which leads to damaging iron accumulation in the tissues, especially the heart. Ferriprox (deferiprone) is an iron chelator that effectively removes the excess iron from the body caused by blood transfusions.
Catalyst Biosciences Selects Drug Development Candidate In Factor VIIa Program For Hemophilia published
Wed, 07 May 2008 00:00:00 PDT
Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, announced that it has selected CB 813, an improved, second-generation variant of human coagulation factor VIIa, as a development candidate for the treatment of acute bleeding in hemophilia patients. CB 813 was created using Catalyst's proprietary therapeutic protease platform technologies and know-how.
Nix Essential To Red Blood Cells published
Mon, 05 May 2008 04:00:00 PDT
A process of self-digestion called autophagy prompts the maturation of red blood cells. Without a protein called Nix, the cells would not effectively rid themselves of organelles called mitochondria and consequently become short-lived, leading to anemia, said researchers at Baylor College of Medicine in Houston in a report that appears online in the journal Nature."It's changed our thinking on autophagy," said Dr.
Studies Point To Benefits Of Personalized Chemotherapy Dose Management In Colorectal Cancer published
Sat, 03 May 2008 00:00:00 PDT
Can a blood test improve treatment outcomes for colorectal cancer patients? Recently published studies indicate that personalized chemotherapy dose management -- measuring drug levels in patients' blood and adjusting them for optimal dosing -- can substantially reduce severe toxicity and improve efficacy in colorectal cancer. A Phase III randomized study of 208 colorectal cancer patients, by Erick Gamelin, M.D., Ph.D. et. al.
St. Jude Medical Announces U.S. Launch Of TigerWire Steerable Guidewire published
Fri, 02 May 2008 03:00:00 PDT
St. Jude Medical, Inc. (NYSE:STJ) announced U.S. launch of the TigerWire(TM) Steerable Guidewire. The newest member of the St. Jude Medical GuideRight(TM) family of steerable guidewires, the TigerWire Steerable Guidewire is designed to enhance physicians' ability to steer through challenging peripheral arteries, the vessels that supply blood to the legs and arms.
Studies Look At Blacks' Noncompliance With Weekly Dialysis Treatment; Provider, Patient Satisfaction With Telephone Interpretation Services published
Thu, 01 May 2008 10:00:00 PDT
"Dialysis 'No-Shows' on Saturdays: Implications of the Weekly Hemodialysis Schedules on Nonadherence and Outcomes," (.
Hydrogen Sulphide May Be Involved In Regulating Blood Pressure published
Wed, 30 Apr 2008 03:00:00 PDT
Hydrogen sulphide (H2S) is a gas most commonly associated with the smell of stink bombs, sewage and rotten eggs, but a team of researchers from the Peninsula Medical School in the South West of England and King's College London have now identified a role for this gas in regulating blood pressure, according to research published in the leading science journal Circulation.
Heparin Testimonies Before House Committee published
Wed, 30 Apr 2008 03:00:00 PDT
Emotions ran high in Washington yesterday, Tuesday 29th April, as a congressional panel listened to tearful and angry testimonies from family members of how their loved ones died after being given contaminated heparin. Manufacturers and industry regulators also told their story, but panel members were very unhappy with their failure to stop the unsafe blood thinner from entering the US from China.
Testimony Of Baxter Int. CEO Before Subcommittee On Oversight And Investigations Committee On Energy And Commerce U.S. House Of Representatives published
Tue, 29 Apr 2008 16:00:00 PDT
SUMMARY OF MAJOR POINTS-- More than any other company in the world, Baxter's products are involved in critical caresettings. Because of this, we are greatly concerned that our heparin product appears to be thetarget of a deliberate adulteration scheme. Patient safety is our number one priority, and wedeeply regret the impact this contamination in Baxter's heparin has had on patients and theclinicians who treat them.
Viscosity Enhancers That Thicken Blood Are Highly Effective In Treating Severe Hemorrhage published
Tue, 29 Apr 2008 02:00:00 PDT
Intravenous administration of isotonic fluids is the standard emergency treatment in the U.S. for patients with severe blood loss, but UC San Diego bioengineering researchers have reported improved resuscitation with a radically different approach. Building on earlier studies in humans that have shown benefits of intravenous fluids that are eight times saltier than normal saline, the researchers combined hypertonic saline with viscosity enhancers that thicken blood.
Clumps Of Red And White Blood Cells May Contribute To Sickle Cell Disease published
Tue, 29 Apr 2008 00:00:00 PDT
It's long been known that patients with sickle cell disease have malformed, "sickle-shaped" red blood cells which are normally disc-shaped that can cause sudden painful episodes when they block small blood vessels.Now, researchers at the University of North Carolina at Chapel Hill School of Medicine have shown that blood from sickle cell patients also contains clumps, or aggregates, of red and white blood cells that may contribute to the blockages.
Adverse Outcomes Linked To Hemoglobin-Based Blood Substitutes published
Mon, 28 Apr 2008 11:00:00 PDT
A meta-analysis published in JAMA reports that theuse of hemoglobin-basedblood substitutes is associated with an increasedrisk of heart attack and death.Blood substitutes are liquids that have long shelf lives, do not needto be refrigerated, and do not cause infection.
Ligand Initiates Phase II Trial With LGD-4665 In Idiopathic Thrombocytopenic Purpura published
Mon, 28 Apr 2008 01:00:00 PDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has initiated a Phase II study of its small-molecule thrombopoietin (TPO) mimetic, LGD-4665. The 24 patient, double-blind placebo-controlled trial is designed to evaluate the safety and efficacy of LGD-4665 in adult patients with idiopathic thrombocytopenic purpura (ITP) over six weeks of treatment.
Lannett Company Receives Approval For Dipyridamole Tablets USP, 25 Mg, 50 Mg, And 75 Mg published
Mon, 28 Apr 2008 01:00:00 PDT
Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Dipyridamole Tablets USP, 25mg, 50mg, and 75mg, the generic equivalent of Persantine® Tablets manufactured by Boehringer Ingelheim GmbH. According to Wolters Kluwer, total sales of generic Dipyridamole Tablets were $46 million a year in 2007 at average wholesale price (AWP).
Tredaptive Recommended For EU Approval For The Treatment Of Mixed Dyslipidaemia And Primary Hypercholesterolaemia published
Mon, 28 Apr 2008 01:00:00 PDT
Merck Sharp & Dohme Limited (MSD) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for 'Tredaptive'™ (nicotinic acid/laropiprant, MSD) 1000 mg / 20 mg modified-release tablets for the treatment of mixed dyslipidaemia and primary hypercholesterolaemia.
Publication Offers Labs Consensus Recommendations For Diagnosing Parasitic Diseases published
Mon, 28 Apr 2008 00:00:00 PDT
ASM Press announces the latest addition to its Cumulative Techniques and Procedures in Clinical Microbiology (Cumitechs) publication series: Cumitech 46 -- Laboratory Procedures for Diagnosis of Blood-Borne Parasitic Diseases."This Cumitech is intended to provide guidance to the laboratory personnel and other members of the patient care team in the appropriate selection, ordering and application of tests for the diagnosis and management of blood-borne parasitic infections.
University Hospitals Of Leicester NHS Trust Acquires Complete Blood Science Requirements From A Single Source, UK published
Fri, 25 Apr 2008 15:00:00 PDT
In a landmark deal with Siemens Healthcare Diagnostics, the University Hospitals of Leicester NHS Trust has opted for a total pathology solution to meet all its blood science analytical requirements.
Clexane Recall, Australian Medical Association published
Fri, 25 Apr 2008 04:00:00 PDT
The AMA would like to clarify comments made last Wednesday in the context of the recall of batches of Clexane in Australia. Whilst contaminated heparin products have been linked to several severe allergic reactions and deaths in the US and Europe, the AMA has no information to suggest that Clexane was involved in such events. The AMA understands that to date, no adverse events associated with contaminated heparin products have been reported in Australia.
Vermillion And The Ohio State University Report That Novel Diagnostic Test May Help Predict Risk For Relapse Of TTP, A Serious Blood Disorder published
Fri, 25 Apr 2008 00:00:00 PDT
Vermillion, Inc. (Nasdaq: VRML) reported findings from an Ohio State University (OSU) clinical study that indicated that a surface-enhanced laser desorption/ionization time of flight (SELDI-TOF)-based thrombotic thrombocytopenic purpura (TTP) diagnostic test could be used to help estimate the risk of TTP relapses during clinical remission.
MIT-Led Teams Unravel Heparin Death Mystery published
Thu, 24 Apr 2008 02:00:00 PDT
An international team of researchers led by MIT has explained how contaminated batches of the blood-thinner heparin were able to slip past traditional safety screens and kill dozens of patients recently in the United States and Germany. The team, led by Professor Ram Sasisekharan of MIT, identified the chemical structure of the contaminant, known as oversulfated chondroitin sulfate (OSCS).
)
|
|
